Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Howmet Aerospace Inc (HWM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Howmet Aerospace Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $302.38 (market cap $39.89B), while Howmet Aerospace Inc trades at $272.44 (market cap $108.37B). The key difference: Howmet Aerospace Inc is far larger — about 2.7× Alnylam Pharmaceuticals, Inc.'s market cap, and Howmet Aerospace Inc pays a 0.18% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | HWM | |
|---|---|---|
Market Cap | $39.89B | $108.37B |
Sector | Health | Industrials |
52-Week High | $491.22 | $283.23 |
52-Week Low | $278.09 | $171.00 |
Enterprise Value | $38.15B | $110.62B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Howmet Aerospace (HWM) trades at $270.85, down 1.07% on the day, with a bullish technical outlook supported by moving averages and key support at $268. The company reported strong profitability with a 20.22% net margin and ROE of 33.98%, though Q1 2026 earnings missed expectations. Recent news highlights growth in commercial aerospace and defense sectors, with Q2 2026 results due August 6, 2026.
HWM's premium valuation (P/E 62.84) reflects growth optimism, but execution risks and earnings volatility pose challenges. Analyst consensus is bullish with a $317.29 price target, suggesting 17% upside. Investors should weigh robust cash flow and sector tailwinds against high multiples and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Howmet Aerospace Inc
Howmet Aerospace provides advanced engineered solutions for the aerospace and transportation industries. It specializes in jet engine components, aerospace fastening systems, and forged aluminum wheels.
Read more on HWM →
